Allison Elliott-Shannon

By

College: Medicine

Study Shows New Drug Compound Reduces Alzheimer's Pathology in Animal Model

Published: Jul 25, 2012

 

LEXINGTON, Ky. (July 25, 2012) — In a study published in the Journal of Neuroscience, a collaborative team of researchers led by Linda J. Van Eldik, director of the University of Kentucky Sanders-Brown Center on Aging, and D. Martin Watterson of the Northwestern University Feinberg School of Medicine, present results showing that a new central nervous system drug compound can reduce Alzheimer’s pathology in a mouse model of the disease.

 

The drug, called MW-151, is a selective suppressor of brain inflammation and overproduction of proinflammatory molecules from glial cells. The drug can be taken by mouth and readily enters the brain. The new study tested the hypothesis that intervention with drugs like MW-151 could be effective as a preventive measure, when administered at an early stage before Alzheimer's pathology appears, as well as after disease symptoms have begun to appear.

 

"Early intervention with MW-151 in an Alzheimer's mouse model reduced the glial activation and proinflammatory cytokine overproduction, which resulted in improvement in neurologic outcomes," said Van Eldik. "The neurological outcomes included protection against the loss of critical nerve cell proteins and functional damage associated with learning and memory impairments."

 

In addition, the drug showed efficacy either before or after Alzheimer's disease was apparent, but was more effective when it was given before the disease was too far advanced, said Van Eldik. "The data support the hypothesis that selectively attenuating certain aspects of dysregulated brain inflammation is beneficial, especially when used early in the disease progression," she said.  "The outcomes suggest that therapeutic strategies targeting this pathological process have the potential to attenuate disease onset and progression."

In other words, administering the drug MW-151 early in the progression of Alzheimer's disease in an animal model resulted in improved outcomes, suggesting that administration of this drug before Alzheimer's symptoms are readily apparent may be a promising therapeutic strategy.  

 

Alzheimer’s disease is the sixth-leading cause of death in the United States, yet it is the only disease among the top 10 killers without a way to prevent, cure or slow its progression. The disease kills more people than diabetes, as well as more people than breast cancer and prostate cancer combined. The recent National Alzheimer’s Project Act clearly defines the rapidly growing nature of the problem and is the foundation for an evolving national plan to address this critical health and economic crisis.  Part of the national effort is to test explicit hypotheses about new disease modifying therapeutic strategies. 

 

Alzheimer's disease is a progressive disease that slowly destroys brain function, leading to memory impairments, difficulties with language and decision-making and eventually the inability to engage in normal activities of daily living and self care. The root causes of Alzheimer's are not understood. However, a rapidly growing body of experimental data and clinical observations on patients raise the possibility that unregulated brain inflammation, termed neuroinflammation, is a factor in susceptibility of disease onset and a contributor to disease progression. 

 

Regardless of neuroinflammation’s exact role, a prevailing hypothesis is that targeting of proinflammatory cytokine overproduction in the brain might be a useful therapeutic strategy to add to the armamentarium of emerging interventions. The primary brain cell target for such a disease modifying strategy would be glia, cells in the brain that produce proinflammatory cytokines and other innate immunity responses to injury or disease progression.  Glial cells normally cooperate with the nerve cells to keep the brain operating smoothly.  When an injury or change in the brain occurs, the glial cells mount a beneficial inflammation response to fight off the insult and restore the brain to its proper functioning. This beneficial process sometimes gets out of balance and the inflammation becomes too strong or does not shut off on schedule.

 

In AD, glial cells are over-activated and produce detrimental inflammatory molecules, which include the small proteins called proinflammatory cytokines, that contribute to nerve cell dysfunction or death. Drugs that selectively target cytokine up-regulation in glia are logical first attempts at this therapeutic strategy.

 

MEDIA CONTACT: Allison Elliott, allison.elliott@uky.edu

 

dsc_2763_vaneldiklabphoto2012.jpg
December
 
1
Resumes and Cover Letters
Circle of Love Gift Return
Mon
2
UK Guitar Studio
Circle of Love Gift Return
Tue
3
Networking and Job Search
Internship Info Session
LNFS Presents: Wayne's World
Study Sounds: Classical Concert
Wed
4
LNFS Presents: Frozen
Ballet Music of Tchaikovsky
Circle of Love Gift Pick-Up
Live Screening of Orion Spacecraft Re-entry
Massage on the Go
Thu
5
LNFS Presents: Winter's Bone
LNFS Presents: Gremlins
Open Studio
Circle of Love Gift Pick-Up
Fri
6
Snow Skiing @ Perfect North Slopes
Sat
7
Free Holiday Shopping Shuttle to Fayette Mall
Sun
8
Undergraduate Research Information Session "How to Find a Faculty Mentor"
Mon
9
Job Club - Identifying Your Skills
Paws for Stress Relief
Tue
10
 
Wed
11
 
Thu
12
Last Day of Classes
Fri
13
 
Sat
14
Free Holiday Shopping Shuttle to Fayette Mall
Finals Treats
Sun
15
Final Exams
Crunch Brunch
Mon
16
Final Exams
Jazzy Holiday Concert
Tue
17
Final Exams
Caregiver Support Group
Wed
18
Final Exams
Thu
19
Final Exams
End of 2014 Fall Semester
Fri
20
 
Sat
21
 
Sun
22
 
Mon
23
 
Tue
24
 
Wed
25
 
Thu
26
 
Fri
27
 
Sat
28
 
Sun
29
 
Mon
30
 
Tue
31
 
Wed
 
 
 
Jan 14
Bicycle Trivia 01/14/2015

Wed, 01/14/2015

Fri, 01/16/2015

Wed, 01/21/2015

Reset Page